U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07389941) titled 'Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation' on Jan. 28.
Brief Summary: To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Atrial Fibrillation (AF)
Intervention:
DRUG: Semaglutide (SEMA)
Catheter ablation for AF plus semaglutide (up to 2.4 mg weekly)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: University of Luebeck
Information p...